PTPN14 interacts with and negatively regulates the oncogenic function of YAP

Oncogene

Volumn 32, Issue 10, 2013, Pages 1266-1273

  Liu, X ^a   Yang, N ^a   Figel, S A ^a   Wilson, K E ^a   Morrison, C D ^a   Gelman, I H ^a   Zhang, J ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

epithelial To mesenchymal transition (EMT); Hippo pathway; PTPN14; tumor metastasis; YAP

Indexed keywords

LUCIFERASE; PROTEIN; PROTEIN NON RECEPTOR TYROSINE PHOSPHATASE 14; UNCLASSIFIED DRUG;

ACTIN MYOSIN INTERACTION; ARTICLE; CANCER GENETICS; CELL MIGRATION; CONTROLLED STUDY; GENE; GENE CONTROL; GENE FUNCTION; GENE INTERACTION; GENETIC REGULATION; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; ONCOGENE; PRIORITY JOURNAL; PROTEIN INTERACTION; YAP GENE;

AMINO ACID SEQUENCE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL NUCLEUS; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HUMANS; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; PROTEIN TYROSINE PHOSPHATASES, NON-RECEPTOR; SIGNAL TRANSDUCTION; SUBCELLULAR FRACTIONS; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION;

EID: 84874767303     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.147     Document Type: Article

References (49)

1. Harvey K, Tapon N. The Salvador-Warts-Hippo pathway - an emerging tumoursuppressor network. Nat Rev Cancer 2007; 7: 182-191.
2. Zhao B, Tumaneng K, Guan KL. The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat Cell Biol 2011; 13: 877-883.
3. Pan D. The hippo signaling pathway in development and cancer. Dev Cell 2010; 19: 491-505.
4. Mauviel A, Nallet-Staub F, Varelas X. Integrating developmental signals: a Hippo in the (path)way. Oncogene 2012; 31: 1743-1756.
5. Harvey KF, Pfleger CM, Hariharan IK. The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell 2003; 114: 457-467.
6. Tapon N, Harvey KF, Bell DW, Wahrer DC, Schiripo TA, Haber DA et al. salvador Promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. Cell 2002; 110: 467-478.
7. Udan RS, Kango-Singh M, Nolo R, Tao C, Halder G. Hippo promotes proliferation arrest and apoptosis in the Salvador/Warts pathway. Nat Cell Biol 2003; 5: 914-920.
8. Huang J, Wu S, Barrera J, Matthews K, Pan D. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell 2005; 122: 421-434.
9. Lai ZC, Wei X, Shimizu T, Ramos E, Rohrbaugh M, Nikolaidis N et al. Control of cell proliferation and apoptosis by mob as tumor suppressor, mats. Cell 2005; 120: 675-685.
10. Sudol M, Chen HI, Bougeret C, Einbond A, Bork P. Characterization of a novel protein-binding module-The WW domain. FEBS Lett 1995; 369: 67-71.
11. Sudol M. Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. Oncogene 1994; 9: 2145-2152.
12. Komuro A, Nagai M, Navin NE, Sudol M. WW domain-containing protein YAP associates with ErbB-4 and acts as a co-Transcriptional activator for the carboxylterminal fragment of ErbB-4 that translocates to the nucleus. J Biol Chem 2003; 278: 33334-33341.
13. Strano S, Munarriz E, Rossi M, Castagnoli L, Shaul Y, Sacchi A et al. Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J Biol Chem 2001; 276: 15164-15173.
14. Alarcon C, Zaromytidou AI, Xi Q, Gao S, Yu J, Fujisawa S et al. Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways. Cell 2009; 139: 757-769.
15. Yagi R, Chen LF, Shigesada K, Murakami Y, Ito YA. WW domain-containing yesassociated protein (YAP) is a novel transcriptional co-activator. EMBO J 1999; 18: 2551-2562.
16. Zhao B, Ye X, Yu J, Li L, Li W, Li S et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 2008; 22: 1962-1971.
17. Vassilev A, Kaneko KJ, Shu H, Zhao Y, DePamphilis ML. TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. Genes Dev 2001; 15: 1229-1241.
18. Zaidi SK, Sullivan AJ, Medina R, Ito Y, van Wijnen AJ, Stein JL et al. Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. EMBO J 2004; 23: 790-799.
19. Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci USA 2006; 103: 12405-12410.
20. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890.
21. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011; 331: 1559-1564.
22. Zhang J, Smolen GA, Haber DA. Negative regulation of YAP by LATS1 underscores evolutionary conservation of the Drosophila Hippo pathway. Cancer Res 2008; 68: 2789-2794.
23. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 2007; 21: 2747-2761.
24. Hao Y, Chun A, Cheung K, Rashidi B, Yang X. Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Biol Chem 2008; 283: 5496-5509.
25. Zhao B, Li L, Tumaneng K, Wang CY, Guan KL. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev 2010; 24: 72-85.
26. Wang W, Huang J, Chen J. Angiomotin-like proteins associate with and negatively regulate YAP1. J Biol Chem 2011; 286: 4364-4370.
27. Zhao B, Li L, Lu Q, Wang LH, Liu CY, Lei Q et al. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev 2011; 25: 51-63.
28. Chan SW, Lim CJ, Chong YF, Pobbati AV, Huang C, Hong W. Hippo pathwayindependent restriction of TAZ and YAP by angiomotin. J Biol Chem 2011; 286: 7018-7026.
29. Oka T, Schmitt AP, Sudol M. Opposing roles of angiomotin-like-1 and zona occludens-2 on pro-apoptotic function of YAP. Oncogene 2012; 31: 128-134.
30. Schlegelmilch K, Mohseni M, Kirak O, Pruszak J, Rodriguez JR, Zhou D et al. Yap1 acts downstream of alpha-catenin to control epidermal proliferation. Cell 2011; 144: 782-795.
31. Varelas X, Samavarchi-Tehrani P, Narimatsu M, Weiss A, Cockburn K, Larsen BG et al. The Crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-beta-SMAD pathway. Dev Cell 2010; 19: 831-844.
32. Oka T, Remue E, Meerschaert K, Vanloo B, Boucherie C, Gfeller D et al. Functional complexes between YAP2 and ZO-2 are PDZ domain-dependent, and regulate YAP2 nuclear localization and signalling. Biochem J 2010; 432: 461-472.
33. Silvis MR, Kreger BT, Lien WH, Klezovitch O, Rudakova GM, Camargo FD et al. alpha-catenin is a tumor suppressor that controls cell accumulation by regulating the localization and activity of the transcriptional coactivator Yap1. Sci Signal 2011; 4: ra33.
34. Sawada M, Ogata M, Fujino Y, Hamaoka T. cDNA cloning of a novel protein tyrosine phosphatase with homology to cytoskeletal protein 4.1 and its expression in T-lineage cells. Biochem Biophys Res Commun 1994; 203: 479-484.
35. Wadham C, Gamble JR, Vadas MA, Khew-Goodall Y. Translocation of protein tyrosine phosphatase Pez/PTPD2/PTP36 to the nucleus is associated with induction of cell proliferation. J Cell Sci 2000; 113(Pt 17): 3117-3123.
36. Chen HI, Sudol M. The WW domain of Yes-associated protein binds a proline-rich ligand that differs from the consensus established for Src homology 3-binding modules. Proc Natl Acad Sci USA 1995; 92: 7819-7823.
37. Sudol M, Harvey KF. Modularity in the Hippo signaling pathway. Trends Biochem Sci 2010; 35: 627-633.
38. Ogata M, Takada T, Mori Y, Oh-hora M, Uchida Y, Kosugi A et al. Effects of overexpression of PTP36, a putative protein tyrosine phosphatase, on cell adhesion, cell growth, and cytoskeletons in HeLa cells. J Biol Chem 1999; 274: 12905-12909.
39. Ogata M, Takada T, Mori Y, Uchida Y, Miki T, Okuyama A et al. Regulation of phosphorylation level and distribution of PTP36, a putative protein tyrosine phosphatase, by cell-substrate adhesion. J Biol Chem 1999; 274: 20717-20724.
40. Wyatt L, Khew-Goodall Y. PTP-Pez: a novel regulator of TGFbeta signaling. Cell Cycle 2008; 7: 2290-2295.
41. Smith AL, Mitchell PJ, Shipley J, Gusterson BA, Rogers MV, Crompton MR. Pez: a novel human cDNA encoding protein tyrosine phosphatase- and ezrin-like domains. Biochem Biophys Res Commun 1995; 209: 959-965.
42. Wadham C, Gamble JR, Vadas MA, Khew-Goodall Y. The protein tyrosine phosphatase Pez is a major phosphatase of adherens junctions and dephosphorylates beta-catenin. Mol Biol Cell 2003; 14: 2520-2529.
43. Poernbacher I, Baumgartner R, Marada SK, Edwards K, Stocker H. Drosophila pez acts in hippo signaling to restrict intestinal stem cell proliferation. Curr Biol 2012; 22: 389-396.
44. Xiao L, Chen Y, Ji M, Dong J. KIBRA regulates Hippo signaling activity via interactions with large tumor suppressor kinases. J Biol Chem 2011; 286: 7788-7796.
45. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314: 268-274.
46. Wang Z, Shen D, Parsons DW, Bardelli A, Sager J, Szabo S et al. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 2004; 304: 1164-1166.
47. Niedergethmann M, Alves F, Neff JK, Heidrich B, Aramin N, Li L et al. Gene expression profiling of liver metastases and tumour invasion in pancreatic cancer using an orthotopic SCID mouse model. Br J Cancer 2007; 97: 1432-1440.
48. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF- 10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003; 30: 256-268.
49. Zhang J, Ji JY, Yu M, Overholtzer M, Smolen GA, Wang R et al. YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nat Cell Biol 2009; 11: 1444-1450.